NOV 20, 2020 7:30 AM PST

Cat Parasite Gives Clues on New Drug Targets for Schizophrenia

WRITTEN BY: Annie Lennon

Researchers from the UK and France have discussed a mechanism of action behind the infamous Toxoplasma gondii parasite transferred to humans from cat litter that may lead to the development of new treatments for schizophrenia and other neurological disorders. 

Estimates say that between 30% and 50% of the world’s population is infected with the parasite. While those infected are usually asymptomatic, it is known to cause headaches, confusion, and seizures in others. It is also linked to an increase in the risk of developing schizophrenia and behavioral changes in rodents. 

T. gondii is only able to sexually reproduce in cats. In doing so, it forms cysts that are excreted in the cat’s feces, where they can then enter new hosts via ingestion of anything contaminated by them. This includes water, soil, vegetables, blood transfusions, and mother to fetus. Virtually any warm-blooded animal may be a host.

After being infected, the infection enters a dormant phase within a few weeks, during which it forms cysts in the brain. These cysts remain there for years, where they affect neurotransmitter norepinephrine levels. 

In their new study, the researchers found that the parasite’s ability to reduce norepinephrine disrupts the body’s ability to regulate the immune system. This then leads to an overactive immune response, which may then change the host’s cognitive functions. 

“Our insight connects the two opposing theories for how Toxoplasma alters host behavior and this may apply to other infections of the nervous system,” says Glenn McConkey, one of the researchers behind the paper. “

One school believes that behavior changes are invoked by the immune response to infection and the other that changes are due to altered neurotransmitters.”

The researchers say that their findings will contribute to our understanding of the link between brain inflammation and cognition. As such, they hope that their work will go on to inform the development of antipsychotic treatments. 

 

Sources: Neuroscience NewsTrends in Immunology

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
OCT 01, 2020
Drug Discovery & Development
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
OCT 01, 2020
HPV Vaccine Protects Against Cervical Cancer, Large Study Finds
It has been known for some time that the HPV vaccine protects against human papillomavirus infection, genital warts, and ...
NOV 11, 2020
Health & Medicine
A smart path for novel biologics
NOV 11, 2020
A smart path for novel biologics
Introduction  Cell culture is at the heart of the production process for many biopharmaceuticals, but finding the o ...
OCT 03, 2020
Drug Discovery & Development
Treating Gut-Leakiness
OCT 03, 2020
Treating Gut-Leakiness
A drug called tofacitinib, also called Xeljanz , was found to treat permeability defects in the intestines. Tofacitinib ...
OCT 18, 2020
Drug Discovery & Development
Virus-Mimicking Drug
OCT 18, 2020
Virus-Mimicking Drug
Scientists have found drug that a drug activates the body’s immune system by behaving like a virus and may make ce ...
NOV 08, 2020
Neuroscience
Psychedelic DMT Improves Memory by Neurogenesis
NOV 08, 2020
Psychedelic DMT Improves Memory by Neurogenesis
Researchers from the Complutense University of Madrid in Spain have found that dimethyltryptamine (DMT), the psychoactiv ...
NOV 18, 2020
Drug Discovery & Development
Hepatitis C Drugs May Be Involved Coronavirus Treatment
NOV 18, 2020
Hepatitis C Drugs May Be Involved Coronavirus Treatment
At the present moment, there are no inhibitors that target protease activity of the novel SARS-CoV-2. The main proteases ...
Loading Comments...